SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares recently surged following reports that the streaming company is exploring a potential sale, with major media firms reportedly among the interested parties. Investors are actively debating the likelihood of a buyout, weighing potential premium pricing against Roku's strengthening platform growth and its critical position as a gatekeeper in the connected TV advertising ecosystem.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as a key player in the decentralized AI sector, driven by a structural narrative that positioning it as a permissionless, global alternative to the increasingly restricted and centralized AI models offered by big tech. The community is actively debating the network's long-term utility versus its risks, while many are focused on the integration of subnets and the broader potential of decentralizing AI infrastructure.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending following an overwhelming shareholder vote to approve the $110 billion merger with Paramount Skydance, marking a major milestone for this media megadeal. While the merger faces continued antitrust scrutiny from regulators and some pushback from Hollywood creators, the market is actively monitoring the deal's path to closing and the implications for industry consolidation.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh strong Phase 3 clinical data for its gene-editing HAE therapy against a recent equity offering, which has sparked intense debate over dilution and potential short-squeeze dynamics. The community remains focused on the company's long-term commercial potential, institutional accumulation, and whether the recent capital raise serves as a strategic runway or a near-term headwind.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened volatility as investors debate its long-term viability amidst broader cryptocurrency market pressure and speculation surrounding potential ties to Elon Musk's companies. While some community members remain optimistic, citing previous support levels and future catalysts, others express skepticism, viewing the recent price action as a sign of fading momentum.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is currently trending as investors focus on its potential as a sovereign cloud infrastructure alternative to Big Tech, driven by ongoing deployments like the Pakistan subnet and the anticipation of new product rollouts. Community discourse reflects a split between long-term holders encouraged by fundamental network growth and utility, and skeptical traders wary of historical volatility and price performance.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is facing heightened scrutiny as it caps withdrawals on a flagship private credit fund following a surge in redemption requests, fueling broader market concerns about liquidity and loan quality in the sector. Investors are actively discussing the potential systemic risks of these private credit constraints, especially as the firm's stock reacts to both negative valuation write-downs and its ongoing expansion into tokenized assets and crypto ETFs.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is drawing attention as a potential M&A target amid ongoing market speculation, with investors closely watching institutional activity and the company's aggressive pipeline expansion. Community sentiment remains focused on the drug's long-term commercial potential and the likelihood of a high-premium buyout as institutional investors weigh growth versus profitability.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending as investors focus on the company's expanding RNAi pipeline, particularly its obesity candidates ARO-INHBE and ARO-ALK7, following recent interim clinical data. Community discussion is heavily fixated on the firm's strategic positioning for M&A, the potential of its TRiM delivery platform, and ongoing frustration with perceived algorithmic stock manipulation.

PolySwarm

PolySwarm ($NCT) is capturing community attention due to its extremely low float and persistent chatter about its potential for momentum-driven price action in the cybersecurity sector. Investors are closely monitoring the token's technical consolidation and tight price action, with many discussing its long-term utility while actively looking for signs of a significant breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AMRN  I have no probelem with the firm giving guidance when they are ready .  It may be next quarter .

Stocktwits

Amarin Corp - ADR

  I have no probelem with the firm giving guidance when they are ready .  It may be next quarter .

Scott Thomas

@drivethelane2001 I&#39;m with you.. I was bullish last year, but have become more neutral now

 I'm with you.. I was bullish last year, but have become more neutral now

@shandal  Take J he&#39;s always super positive on stock . That&#39;s fine . If we get NCE then yes issues turn real fast . If and when .

  Take J he's always super positive on stock . That's fine . If we get NCE then yes issues turn real fast . If and when .

@drivethelane2001 I thought February, but no decision.. who knows

 I thought February, but no decision.. who knows

@shandal you are aware of the huge mistakes made at FDA .some firms that recd NCE lost it later and just the opposite .

 you are aware of the huge mistakes made at FDA .some firms that recd NCE lost it later and just the opposite .

@drivethelane2001 any guesses on what we&#39;re waiting on? I think it&#39;s legal too, but does that mean lawyers signing off stuff I assume

 any guesses on what we're waiting on? I think it's legal too, but does that mean lawyers signing off stuff I assume

@shandal  you need to ask , who losses if we get NCE ...its GSK .

  you need to ask , who losses if we get NCE ...its GSK .

@drivethelane2001 Yes I agree, but what could GSK do at this point.. IMO not much

 Yes I agree, but what could GSK do at this point.. IMO not much

@shandal  They could sue the FDA . It&#39;s not uncommon

  They could sue the FDA . It's not uncommon

@drivethelane2001 I think they should file a citizen&#39;s petition

 I think they should file a citizen's petition

@shandal  AMRN has filed a citizen petition ...NO . WE (AMRN ) IS petitioning the FDA .

  AMRN has filed a citizen petition ...NO . WE (AMRN ) IS petitioning the FDA .

@drivethelane2001 I don&#39;t understand why it&#39;s not public though.. I&#39;d like to see what it says. I&#39;m pretty sure citizen petitions are..

 I don't understand why it's not public though.. I'd like to see what it says. I'm pretty sure citizen petitions are..

@drivethelane2001 (cont.) available to the public

@drivethelane2001 Go to http://stks.co/dME3 and on right side of FDA Law Blog there is a citizen petition tracker. No Amarin...

Fdalawblog

FDA Law Blog

 and on right side of FDA Law Blog there is a citizen petition tracker. No Amarin...

@shandal they are but since this is fluid perhaps N A . U can try F O I A

 they are but since this is fluid perhaps N A . U can try F O I A

@drivethelane2001 I already tried FOIA. I got no response, so I sent an appeal letter. Have not heard back. Spoke with CDER ombudsman..

 I already tried FOIA. I got no response, so I sent an appeal letter. Have not heard back. Spoke with CDER ombudsman..

@shandal THX for link will check . On my Android now .

 THX for link will check . On my Android now .

@drivethelane2001 I&#39;m frustrated, I know you are, and I&#39;m sure many others are... Something will eventually happen

 I'm frustrated, I know you are, and I'm sure many others are... Something will eventually happen